

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2006 (31.08.2006)

PCT

(10) International Publication Number
WO 2006/089613 A1

(51) International Patent Classification:
C12N 9/04 (2006.01)

(21) International Application Number:
PCT/EP2006/000734

(22) International Filing Date: 27 January 2006 (27.01.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/657,041 28 February 2005 (28.02.2005) US

(71) Applicants (for all designated States except US): **BAXTER INTERNATIONAL INC.** [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US). **BAXTER HEALTHCARE S.A.** [CH/CH]; Hertistrasse 2, CH-8304 Wallisellen (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SCHEIFLINGER, Friedrich** [AT/AT]; Michelbeuerngasse 4/17, A-1090 Vienna (AT). **BOEHM, Ernst** [AT/AT]; Muehlweg 94, A-1210 Vienna (AT).

(74) Agent: **PERREY, Ralf**; Müller-Boré & Partner, Grafinger Strasse 2, 81671 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RECOMBINANT CO-EXPRESSION OF VITAMIN K EPOXIDE REDUCTASE SUBUNIT 1 TO IMPROVE VITAMIN K DEPENDENT PROTEIN EXPRESSION

(57) Abstract: The present invention relates to a host organism containing recombinant nucleic acids coding for the vitamin K reductase complex subunit 1 (VKORC1) and recombinant nucleic acids coding for a vitamin K dependent (VKD) protein, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said host organism. Further, the present invention relates to a cell culture system comprising cells which contain said recombinant nucleic acids and to methods for improving the productivity of recombinant VKD protein expression in a host organism being cultured in suitable systems.

RECOMBINANT CO-EXPRESSION OF VITAMIN K EPOXIDE REDUCTASE SUBUNIT 1 TO IMPROVE VITAMIN K DEPENDENT PROTEIN EXPRESSION

FIELD OF THE INVENTION

[001] The present invention relates to a host organism containing recombinant nucleic acids coding for the vitamin K reductase complex subunit 1 (VKORC1) and recombinant nucleic acids coding for a vitamin K dependent (VKD) protein, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said host organism. Further, the present invention relates to a cell culture system comprising cells which contain said recombinant nucleic acids and to methods for improving the productivity of recombinant VKD protein expression in a host organism being cultured in suitable systems.

BACKGROUND OF THE INVENTION

[002] The vitamin K epoxide reductase complex (VKORC) recycles the reduced form of vitamin K which is an essential cofactor for post-translational γ -carboxylation of vitamin K dependent (VKD) proteins (Nelsestuen, G.L., Zytkevich, T.H., & Howard, J.B. (1974) The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. *J.Biol.Chem.*, 249, 6347-6350). The VKORC1 gene was identified recently, and is described in detail in Rost *et al.*, 2004 (Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hortnagel, K., Pelz, H.J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E.G., Muller, C.R., Strom, T.M., & Oldenburg, J. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. *Nature*, 427, 537-541).

[003] VKD proteins contain γ -carboxylated glutamate (gla) residues giving them specific biochemical and physiological properties like Ca-dependent binding to negatively charged phospholipid membranes in the case of blood clotting factors (Mann, K.G., Jenny, R.J., & Krishnaswamy, S. (1988) Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. *Annu.Rev.Biochem.*, 57, 915-956). VKD proteins include procoagulant factors II, VII, IX and X, and anticoagulant proteins C, S and Z. Although restricted to one single known enzymatic reaction, γ -carboxylase activity is found in all mammalian tissues (Vermeer, C. & de Boer-van den Berg MA (1985) Vitamin K-dependent carboxylase. *Haematologia (Budap.)*, 18, 71-97). The γ -carboxylase catalyzes a carboxylation reaction using reduced vitamin K as cofactor.

[004] Vitamin K dependent (VKD) gamma carboxylation of glutamic acid residues is a post-translational protein modification required for the generation of biologically active VKD proteins playing roles in hemostasis, growth control, calcium homeostasis, and signal transduction (Furie,B., Bouchard,B.A., & Furie,B.C. (1999) Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. *Blood*, 93, 1798-1808; Berkner,K.L. (2000) The vitamin K-dependent carboxylase. *J.Nutr.*, 130, 1877-1880). Several glutamic acid residues in the N-terminal Gla-domain of these proteins are modified by carboxylation to enable calcium-dependent phospholipid membrane interactions (Stenflo,J. & Suttie,J.W. (1977) Vitamin K-dependent formation of gamma-carboxyglutamic acid. *Annu.Rev.Biochem.*, 46, 157-172; Suttie,J.W. (1980) Mechanism of action of vitamin K: synthesis of gamma-carboxyglutamic acid. *CRC Crit Rev.Biochem.*, 8, 191-223). These multiple gamma-glutamate (Gla) residues allow the Gla domain to undergo conformational changes which are required for the activity of VKD proteins in combination with binding to phospholipid membrane surfaces (Nelsestuen,G.L., Broderius,M., & Martin,G. (1976) Role of gamma-carboxyglutamic acid. Cation specificity of prothrombin and factor X-phospholipid binding. *J.Biol.Chem.*, 251, 6886-6893; Zwaal,R.F., Comfurius,P., & Bevers,E.M. (1998) Lipid-protein interactions in blood coagulation. *Biochim.Biophys.Acta*, 1376, 433-453).

[005] The VKD blood coagulation proteins require full or nearly full carboxylation to bind to membrane surfaces in the presence of calcium ions (Furie,B. & Furie,B.C. (1988) The molecular basis of blood coagulation. *Cell*, 53, 505-518). If vitamin K antagonists inhibit gamma carboxylation, thus undercarboxylated VKD proteins cannot form the calcium dependent structure which results in low affinity to phospholipids membranes and less activity (Esmon,C.T., Sadowski,J.A., & Suttie,J.W. (1975a) A new carboxylation reaction. The vitamin K-dependent incorporation of H-14-CO₃- into prothrombin. *J.Biol.Chem.*, 250, 4744-4748; Esmon,C.T., Suttie,J.W., & Jackson,C.M. (1975b) The functional significance of vitamin K action. Difference in phospholipid binding between normal and abnormal prothrombin. *J.Biol.Chem.*, 250, 4095-4099; Malhotra,O.P., Nesheim,M.E., & Mann,K.G. (1985) The kinetics of activation of normal and gamma-carboxyglutamic acid-deficient prothrombins. *J.Biol.Chem.*, 260, 279-287). For example, contributions to overall protein activity losses could be assigned to the absence of each of the 10 Gla-residues of the VKD protein activated human protein C (Zhang,L., Jhingan,A., & Castellino,F.J. (1992) Role of individual gamma-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity. *Blood*, 80, 942-952). Missing procoagulant activity of undercarboxylated factor IX mutants found in hemophilia B patients can be assigned to impaired calcium-induced conformational changes and loss in the ability to bind phospholipid vesicles (Ware,J., Diuguid,D.L., Liebman,H.A., Rabinet,M.J., Kasper,C.K., Furie,B.C., Furie,B., & Stafford,D.W. (1989) Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties. *J.Biol.Chem.*, 264, 11401-11406).

[006] In case of recombinant factor IX, it has been shown that expression of functional factor IX in Chinese hamster ovary cells is limited by the fact that carboxylation ability is saturated at higher production levels (Kaufman,R.J., Wasley,L.C., Furie,B.C., Furie,B., & Shoemaker,C.B. (1986) Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells. *J.Biol.Chem.*, 261, 9622-9628; Derian,C.K.,

VanDusen,W., Przysiecki,C.T., Walsh,P.N., Berkner,K.L., Kaufman,R.J., & Friedman,P.A. (1989) Inhibitors of 2-ketoglutarate-dependent dioxygenases block aspartyl beta-hydroxylation of recombinant human factor IX in several mammalian expression systems. *J.Biol.Chem.*, 264, 6615-6618).

[007] Recombinant over-expression of γ -carboxylated proteins was shown in case of human factor IX to lead to a limitation of propeptide cleavage and γ -carboxylation at higher secretion rates, thus yielding proteins which are only partially occupied with gla residues also when vitamin K is available in the culture medium in surplus. This leads to the secretion of variants of VKD recombinant proteins with reduced activities. Addition of vitamin K to the medium did not improve factor IX activity at high expression levels. The requirement of vitamin K present in the cell culture medium to elicit active factor IX was shown to reach saturation at 5 μ g/ml. Below this level, the secreted amount of active factor IX from Chinese hamster ovary (CHO) cells was dependent on vitamin K concentration (Kaufman, R.J., Wasley, L.C., Furie, B.C., Furie, B., & Shoemaker, C.B. (1986) Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells. *J.Biol.Chem.*, 261, 9622-9628).

[008] Up to now cell lines with low expression levels have to be chosen for production in order to overcome these limitations of cellular capacity to modify VKD proteins post-translationally. Co-expression of Furin, the propeptide cleaving enzyme, leads to complete cleavage of this propeptide (Wasley, L.C., Rehemtulla, A., Bristol, J.A., & Kaufman, R.J. (1993) PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway. *J.Biol.Chem.*, 268, 8458-8465), but is not involved in γ -carboxylation improvement. Another approach, the overexpressing of γ -carboxylase, has not led to improved protein secretion in case of factor IX (Rehemtulla, A., Roth, D.A., Wasley, L.C., Kuliopulos, A., Walsh, C.T., Furie, B., Furie, B.C., & Kaufman, R.J. (1993) In vitro and in vivo functional characterization of bovine vitamin K-dependent gamma-carboxylase expressed in Chinese hamster ovary cells. *Proc.Natl.Acad.Sci.U.S.A*, 90, 4611-4615). Factor IX molecules, which are bound to the carboxylase during the carboxylation reaction are

not released effectively. It was concluded that the supply of reduced vitamin K form at the site of γ -carboxylation is the limiting step of this reaction (Hallgren, K.W., Hommema, E.L., McNally, B.A., & Berkner, K.L. (2002) Carboxylase overexpression effects full carboxylation but poor release and secretion of factor IX: implications for the release of vitamin K-dependent proteins. *Biochemistry*, 41, 15045-15055).

[009] Therefore, a strong need exists for stabilizing the expression, particularly the recombinant expression of VKD proteins in host organisms yielding in improved secretion rates and/or activities of the expressed VKD proteins.

[010] Thus, it is an object of the present invention to provide new systems and methods for improving the productivity of (particularly recombinant) VKD protein expression via co-expression of VKORC1.

SUMMARY OF THE INVENTION

[011] The present invention relates to a host organism containing a recombinant nucleic acid coding for a vitamin K reductase complex subunit 1 (VKORC1) or a functionally active derivative thereof, and a recombinant nucleic acid coding for a vitamin K dependent (VKD) protein or a functionally active derivative thereof, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said host organism.

[012] Further, the present invention relates to a cell culture system comprising cells which contain a recombinant nucleic acid coding for VKORC1 or a functionally active derivative thereof and a recombinant nucleic acid coding for a VKD protein or a functionally active derivative thereof, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said cells, to methods for improving the productivity of recombinant VKD protein expression or of a functionally active derivative thereof in a host organism by recombinantly co-expressing VKORC1, and to the use of a recombinant expression of VKORC1 in a host organism or cell culture system for improving the productivity of recombinant VKD expression.

DETAILED DESCRIPTION OF THE INVENTION

[013] One aspect of the present invention relates to a host organism containing a recombinant nucleic acid coding for a vitamin K reductase complex subunit 1 (VKORC1) or a functionally active derivative thereof, and a recombinant nucleic acid coding for a vitamin K dependent (VKD) protein or a functionally active derivative thereof, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said host organism.

[014] The term "functionally active derivative" as used herein means any polypeptide with substantially the same biological function as VKORC1 and VKD proteins respectively. The polypeptide sequences of the functionally active derivatives may contain deletions, additions and/or substitution of amino acids whose absence, presence and/or substitution, respectively, do not have any substantial negative impact on the activity of the polypeptide, e.g. amino acids which are located in a part of the polypeptide sequence that does not contribute to the biological activity of the protein. Minor deletions, additions and/or substitutions of amino acids of the respective polypeptide sequences which are not altering the biological activity of said polypeptide are also included in the present application as functionally active derivatives.

[015] In the following the expressions "(recombinant) VKORC1 or a functionally active derivative thereof" and "(recombinant) VKD protein or a functionally active derivative thereof" will also be designated as "(r)VKORC1" and "(r)VKD protein", respectively.

[016] The recombinant nucleic acids of the present invention may be obtained by any method known in the art for the production of recombinant nucleic acids, e.g. via recombinant DNA-technology, reverse transcription of RNA and/or amplification of DNA, or via bacterial reproduction.

[017] The host organism of the present invention may be derived from any host organism, including recombinant host organisms, which is capable of expressing a biologically active rVKORC1 and a biologically active rVKD protein. In particular, the host organism of the present invention may be a eukaryotic host organism, including multicellular organisms, characterized by producing a pharmacologically active rVKD protein.

[018] In one embodiment of the present invention the host organism is a mammalian cell, for example a cell derived from a mammalian cell line selected from the group consisting of CHO cells, HEK293 cells, NS0 cells, Sp20 cells, Perc.6 cells, SkHep cells, HepG2 cells, BHK cells, HeLa cells, Vero cells, and COS cells. In specific examples of the present invention the host organism is a cell derived from CHO cells or HEK293 cells.

[019] In one embodiment of the present invention either the nucleic acid coding for rVKORC1 or the nucleic acid coding for the rVKD protein or both contained in the host organism of the present invention are expressed via an expression mode selected from the group consisting of induced, transient, and permanent expression. Any expression system known in the art or commercially available can be employed for the expression of the recombinant nucleic acids coding for VKORC1 and/or VKD protein, including the use of regulatory systems such as suitable, preferably controllable promoters, enhancers etc.

[020] In a preferred embodiment of the host organism of the present invention either the recombinant nucleic acid coding for VKORC1 or the recombinant nucleic acid coding for a VKD protein or both are stably integrated into the genetic material of the host organism of the present invention.

[021] The host organism of the present invention can be used for the improved expression of rVKD proteins such as blood factors or functionally active derivatives thereof, preferably human procoagulant or anticoagulant blood factors or functionally active derivatives thereof. In a preferred embodiment of the present invention the

rVKD protein is a pharmacologically acceptable human procoagulant blood factor which can be used in the treatment of bleeding disorders.

[022] As an example of the present invention the rVKD protein is a procoagulant blood factor, including factor II, factor VII, factor IX, preferably human factor IX, and factor X, or an anticoagulant blood factor, including protein C, protein S and protein Z.

[023] According to the present invention the host organism contains a recombinant nucleic acid coding for VKORC1 and a recombinant nucleic acid coding for a VKD protein, wherein both the rVKORC1 and the rVKD protein are expressed in said host organism and wherein the productivity of recombinant VKD protein expression is substantially improved.

[024] The term "wherein the productivity of recombinant VKD protein expression is substantially improved" as used herein means that the amount, secretion rate, activity, and/or stability of a recombinantly expressed VKD protein or a functionally active derivative thereof is substantially increased when compared to the expression of the rVKD protein in a host organism which does not co-express rVKORC1.

[025] The improvement of the productivity of recombinant VKD protein expression can be determined by any method known in the art including the isolation, e.g. from a culture medium or by harvesting the host organism, and analysis, e.g. via electrophoresis, chromatography, or immunoadsorption, of the expressed proteins. In a preferred embodiment of the present invention the expression of the rVKD proteins is detected via any known enzyme immuno assay such as an enzyme-linked immuno-sorbent assay (ELISA). Alternatively, the integrity and activity of the rVKD protein may be assessed by measuring the activated partial thromboplastin time (APTT).

[026] Another aspect of the present invention relates to a cell culture system comprising cells which contain a recombinant nucleic acid coding for VKORC1 and a

recombinant nucleic acid coding for a VKD protein, wherein both the rVKORC1 and the rVKD protein are expressed in said cells.

[027] The cell culture system of the present invention may comprise any cell culture system which contains cells capable of expressing a biologically active rVKORC1 and a biologically active rVKD protein. Examples of suitable cells are listed above. In a preferred embodiment the cell culture system of the present invention is an eukaryotic cell system characterized by producing one or more pharmacologically active rVKD proteins.

[028] In one embodiment of the present invention the cell culture system of the present invention comprises a host organism as defined above.

[029] There is no particular limitation to the media, reagents and conditions used for culturing the cells in the cell culture system of the present invention including culturing the cells in a continuous or batchwise manner. In one embodiment of the present invention the cells are cultured under serum-free or serum- and protein-free conditions. In a further embodiment of the present invention conditions are employed under which cells which contain a recombinant nucleic acid coding for VKORC1 or a VKD protein are selectively proliferated, e.g. by using a selective medium.

[030] The desired rVKD protein which has been expressed by the cells of the selected host organism and which, dependent on the transfection/vector-system used, is contained in the cells or secreted into the medium for culturing cells, can be isolated/recovered from the cell culture system using methods known in the art.

[031] It is a further aspect of the present invention to provide a method for improving the specific activity of recombinant VKD protein expressed in a host organism comprising the steps of:

- (a) providing a host organism;

- (b) inserting a recombinant nucleic acid coding for a VKD protein or a functionally active derivative thereof into the host organism of step (a);
- (c) inserting a recombinant nucleic acid coding for VKORC1 into the host organism of step (a); and
- (d) expressing the recombinant nucleic acids of steps (b) and (c).

[032] In one embodiment of the present invention the recombinant nucleic acids coding for VKORC1 or a VKD protein are inserted into the host organism simultaneously via co-transfection. Alternatively, said recombinant nucleic acids are inserted into the host organism sequentially via subsequent transfections.

[033] The recombinant nucleic acids used according to the present invention may be contained in any form and system suitable for the transfection into a host organism including plasmids and viral vectors. The recombinant nucleic acids coding for VKORC1 and a VKD protein, respectively may be both present in one vector molecule or each in one vector molecule, wherein the two different vector molecules may be the same or different. The transfection of the recombinant nucleic acids depends on the transfection system used and may be carried out by any method known in the art or commercially available for transfecting a host organism like for example a eukaryotic cell including electroporation, precipitation, or microinjection.

[034] It is another aspect of the present invention to provide a method for improving the productivity of recombinant VKD protein expression in a host organism comprising the steps of:

- (a) providing a host organism having a recombinant nucleic acid coding for a VKD protein integrated into its genetic material, preferably its genome;
- (b) inserting a recombinant nucleic acid coding for VKORC1 into the host organism of step (a); and
- (c) expressing the nucleic acids of steps (a) and (b).

[035] In a preferred embodiment of the present invention the recombinant nucleic acid coding for a VKD protein is stably expressed.

[036] It is a further aspect of the present invention to provide a method for improving the productivity of recombinant VKD protein expression in a host organism comprising the steps of:

- (a) providing a host organism having a recombinant nucleic acid coding for VKORC1 integrated into its genome;
- (b) inserting a recombinant nucleic acid coding for a VKD protein into the host organism of step (a); and
- (c) expressing the nucleic acids of steps (a) and (b).

[037] In a preferred embodiment of the present invention the recombinant nucleic acid coding for VKORC1 is stably expressed.

[038] According to the present invention the above-defined host-organism or the above-defined cell culture system can be used for improving surprisingly the productivity of recombinant VKD protein expression by co-expression of rVKORC1.

[039] It is further an object of the present invention to provide a rVKD protein obtainable by inserting a recombinant nucleic acid coding for VKORC1 and a recombinant nucleic acid coding for said rVKD protein, expressing said nucleic acids, and recovering said rVKD protein.

[040] The figures show:

Figure 1 shows the concentrations of rFIX in ng/ml (vertical axis) calculated on the basis of ELISA values (Fig. 1A) and the specific activities of rFIX calculated on the basis of clotting activity (APTT) values in mU/ml (vertical axis) (Fig. 1B) after transient transfections of a CHO-derived rFIX producing cell line with rVKORC1 (1)

or an empty vector (2). Serum-free cell culture supernatants were collected after 24 hours.

Figure 2 shows the specific productivities of rFIX in ng rFIX/ 10^6 cells/day (vertical axis) calculated on the basis of ELISA values (Fig. 2A) and the specific activities of rFIX calculated on the basis of clotting activity (APTT) values in mU rFIX/ 10^6 cells/day (vertical axis) (Fig. 2B) after transient transfections of a CHO-derived rFIX producing cell line with rVKORC1 (1) or an empty vector (2). Serum-free cell culture supernatants were collected after 24 hours.

Figure 3 shows the concentrations of rFIX in ng/ml (vertical axis) calculated on the basis of ELISA values (Fig. 3A) and the specific activities of rFIX calculated on the basis of clotting activity (APTT) values in mU/ml (vertical axis) (Fig. 3B) after transient transfections of a HEK293-derived rFIX producing cell line with rVKORC1 (1) or an empty vector (2). Serum-free cell culture supernatants were collected after 24 hours.

Figure 4 shows the specific productivities of rFIX in ng rFIX/ 10^6 cells/day (vertical axis) calculated on the basis of ELISA values (Fig. 4A) and the specific activities of rFIX calculated on the basis of clotting activity (APTT) values in mU rFIX/ 10^6 cells/day (vertical axis) (Fig. 4B) after transient transfections of a HEK293-derived rFIX producing cell line with rVKORC1 (1) or an empty vector (2). Serum-free cell culture supernatants were collected after 24 hours.

Figure 5 shows the specific clotting activities of rFIX in % after transient transfections of a CHO-derived rFIX producing cell line with rVKORC1 (1) or an empty vector (2) (Fig. 5A) and after transient transfections of a HEK293-derived rFIX producing cell line with rVKORC1 (1) or an empty vector (2) (Fig. 5B).

Figure 6 shows the transient expression of rVKORC1 in a CHO-derived cell line stably expressing rFVII. This cell line is transfected transiently with a vector encoding VKORC1 or the same vector without VKORC1 ("empty vector") as a control.

Transfections are carried out in duplicate, and with subsequent use of 5 different vitamin K1 concentrations. Results of rFVII-productivity and -activity measurements in culture supernatants against vitamin K concentrations are shown. Fig. 6A) Productivity values based on ELISA measurements. Fig. 6B) productivity values based on clotting activity measurements. Fig. 6C) specific FVII activity calculation based on FVII-clotting units per μg as determined by ELISA.

Figure 7 shows the transient expression of rVKORC1 in a CHO- and a HEK293-derived cell line stably expressing rFVII. These cell lines are transfected transiently with a vector encoding rVKORC1 or the same vector without rVKORC1 ("empty vector") as a control. Transfections are carried out in duplicate. Results of rFVII-productivity and -activity measurements based on ELISA and FVII- and FVIIa-clotting in culture supernatants are shown. A) CHO-derived cell line. B) HEK293-derived cell line.

Figure 8 shows the stable bicistronic co-expression of rFVII and rVKORC in CHO-DHFR⁻ host cells. rFVII-Productivities of selected clones generated by gene co-amplification with increasing amounts of MTX. Two different human rFVII-encoding expression vectors have been co-transfected with a DHFR-encoding selection plasmid. Fig. 8A) 83 clones transfected with a vector construct causing bicistronic co-expression of rFVII and rVKORC1. Fig. 8B) 133 clones co-transfected with a rFVII-encoding vector.

Figure 9 shows the productivity and specific activity values of CHO-derived clones producing rFVII with and without rVKORC1 bicistronic co-expression generated after stable transfection by subcloning and gene amplification. 133 clones without co-expression and 83 clones with rVKORC1 co-expression are compared in terms of rFVII productivity and specific clotting activity based on ELISA and FVII-clotting measurements of secreted rFVII.

Figure 10 shows an example of a northern blot analysis of gene expression at mRNA level isolated from CHO-derived cell lines. Lane 1: CHO-DHFR⁻ non-transfected cell

line Lane 2: rFVII clone Lanes 3 and 4: two clones having been subsequently transfected with rFVII- and rVKORC1-encoding plasmid vectors as described in Example 4. Lanes 5 to 7: clones having been transfected with a single vector encoding a bicictronic mRNA with rFVII and rVKORC1 sequences coupled via IRES as described in Example 3. Panels A, B and C show the same blot developed after hybridization with three different probes. A) probe for human VKORC1. B) probe for human FVII. C) probe for hamster GAPDH. Designations and sizes of identified mRNAs are given.

Figure 11 shows rFVII expression levels of stably transfected CHO- and HEK293-derived cell clones isolated after 2nd transfection of rFVII-producing cell lines with a rVKORC1-encoding, or a control plasmid. The control is the empty host vector. Productivity values are based on ELISA measurements of secreted rFVII. Fig. 11A) CHO-derived cell clones. Fig. 11B) HEK293-derived cell clones.

Figure 12 shows rFVII expression levels compared against specific activity values of stably transfected CHO- and HEK293-derived cell clones isolated after 2nd transfection of rFVII-producing cell lines with a rVKORC1-encoding or a control plasmid. The control is the empty host vector. Productivity values are based on ELISA measurements of secreted rFVII. Specific activity values are calculated as FVII-clotting units per µg FVII as determined by ELISA. Fig. 12A) shows CHO-derived cell clones, Fig. 12B) HEK293-derived cell clones.

[041] The present invention will be further illustrated in the following examples without any limitation thereto.

EXAMPLES

Example 1: Transient transfection and co-expression of rVKORC1 in rFIX-producing HEK293- and CHO-derived cell lines

[042] The expression of recombinant factor IX (rFIX) is achieved by introducing expression plasmids containing the human factor IX (FIX) encoding DNA sequence under the control of a strong viral promoter into mammalian host cell lines by an appropriate transfection method resulting in cells having the introduced sequences stably integrated into their genomes. The plasmids also confer resistance to a selectable marker drug by delivering the adequate resistance gene(s). In the case of CHO cells, which are able to grow only in presence of nucleotide precursors in the medium because of an enzyme defect of the nucleotide *de-novo* synthesis pathway, the expression of this enzyme, dihydrofolate-reductase (DHFR), is required. This enables co-amplification of the FIX gene by gradually increasing the concentration of methotrexate (MTX), which leads to an increase of copy numbers of both genes, encoding DHFR and rFIX, within the cell's genome. For that purpose, CHO derived cell clones have to be grown also in selective medium lacking nucleotides and nucleotide precursors.

[043] For the identification of human rFIX producing cells, after transfection and addition of the selective drug(s) to the medium, the cell suspension is diluted to enable isolation of single-cell derived clones. After isolation, these cell clones are cultivated to confluency to enable measurement of rFIX content of the cell culture supernatant by enzyme-linked immuno-sorbent assay (ELISA) technique. For that purpose, the cells have to be grown in the absence of any growth promoting fetal bovine serum or components thereof to ensure identification of by the cells secreted rFIX. To ensure a fully functional rFIX protein, vitamin K is added. The supernatant is harvested after 24 hours and analyzed by rFIX-specific ELISA technique. In addition, the protein's integrity and activity is assessed by measuring activated partial thromboplastin time (APTT).

[044] Co-expression of rVKORC1 is accomplished by transient expression techniques using cell lines, which are already selected for rFIX expression. An expression plasmid comprising rVKORC1 cDNA is transfected into these cells without further clone selection. The supernatants are collected from the whole transfected cell pools, and rFIX content and activity are compared to negative controls and normalized for specific rFIX secretion rates to assess effects of rVKORC1 activity.

Materials and methods:

Expression vectors

[045] The expression vectors are cloned according to standard cloning techniques. Briefly, pSV-DHFR is generated by inserting the PstI 1.5 kbp fragment of vector pAdd26SV(A)-3 (Scahill, S.J., Devos, R., Van der, H.J., & Fiers, W. (1983) Expression and characterization of the product of a human immune interferon cDNA gene in Chinese hamster ovary cells. *Proc.Natl.Acad.Sci.U.S.A*, 80, 4654-4658; vector is a gift by Dr. Hauser, GBF Germany) containing murine DHFR into a pSV β vector (Clontech, Palo Alto, CA) providing the SV40 enhancer, early promoter and intron, where the β -galactosidase gene has been removed by NotI digestion, and a polylinker has been inserted. This vector has also been used to generate phact containing the human actin promoter and intron by exchanging the EcoRI/HindIII fragment with the EcoRI/HindIII fragment of ph β APr-1- β gal, which is also a gift by Dr. Hauser. phact-FIX containing wild-type human FIX cDNA with the ala148 polymorphism (McGraw, R.A., Davis, L.M., Noyes, C.M., Lundblad, R.L., Roberts, H.R., Graham, J.B., & Stafford, D.W. (1985) Evidence for a prevalent dimorphism in the activation peptide of human coagulation factor IX. *Proc.Natl.Acad.Sci.U.S.A*, 82, 2847-2851) is generated by EcoRI digestion of pFIX-bluescript, which has been generated by inserting human FIX from a randomly primed human liver cDNA library into pBluescript (Stratagene, La Jolla, CA), and inserting the resulting fragment into phact partially digested with EcoRI.

[046] The vector pCMV-FIX-neo is generated by inserting the EcoRI fragment of vector pFIX-bluescript into pCMV β (Clontech), where the β -gal cDNA has been

removed. Within this vector, the codon for ala is exchanged to thr by site-specific mutagenesis via PCR, changing the naturally occurring polymorphism of ala148 to thr148. The PCR product is re-inserted into the same vector again. The EcoRI fragment of this vector is cloned into pcDNA3.1 (Invitrogen, Carlsbad, CA) to yield pCMV-FIX-neo.

[047] The vector pCMV-VKORC1-EDHpro is generated by using the vector pCEP4-VKORC1 (kindly provided by Prof. Oldenburg, for description see Rost *et al.*, 2004) as a template for PCR. The PCR product containing the rVKORC1 cDNA is cloned into the pCMV-EDHpro vector (Herlitschka, S.E., Falkner, F.G., Schlokot, U., & Dorner, F. (1996) Overexpression of human prothrombin in permanent cell lines using a dominant selection/amplification fusion marker. *Protein Expr.Purif.*, 8, 358-364).

Cell culture and transfections

[048] CHO DUKX/DXB11 cells are obtained from Columbia University (New York, NY) and are cultivated in DMEM/Ham's F12 (1:1) mix (Invitrogen) supplemented with 5 % fetal bovine serum (PAA, Linz, Austria), desoxy-adenosine, adenosine and thymidine (all from Sigma, St. Louis, MO) and L-Glutamine (Invitrogen) and penicillin/streptomycin (Invitrogen). HEK293 cells (ATCC No. CRL-1573) are cultivated in DMEM/Ham's F12 (1:1) mix supplemented with 5 % fetal bovine serum and L-Glutamine and penicillin/streptomycin. For stable transfections, a calcium-phosphate co-precipitation method is used. CHO rFIX cells are generated by co-transfection with the linearized plasmids phact-FIX and pSV-DHFR and by selection in DMEM/Ham's F12 (1:1) mix without hypoxanthine, glycine, and thymidine (Invitrogen) supplemented with 5 % dialyzed FBS (PAA). For gene amplification, MTX (Ebewe, Unterach, Austria) is added in stepwise increased concentrations beginning with 10 nM up to 200 nM. HEK293 cells are transfected with linearized plasmid pCMV-FIX-neo and selected in medium containing 500 µg/ml G418 (Invitrogen). Cell clones are isolated by limited dilution cloning techniques either manually or using a flow cytometric cell sorting technique.

[049] FIX secretion into cell culture supernatants is detected by exchanging the growth medium for serum-free medium supplemented with 10 µg/ml vitamin K1 (Sigma). Supernatants are collected and FIX concentrations are determined by ELISA and clotting assay (activated partial thromboplastine time, APTT). For the calculation of specific secretion rates, cell numbers are counted using a CASY cell counter (Schärfe Systems, Reutlingen, Germany).

[050] For transient co-expression experiments, the non-linearized plasmid pCMV-VKORC1-EDHPro is transfected using Lipofectamine 2000 reagent (Invitrogen). The same vector without rVKORC1 cDNA is used as negative control.

Analytical methods

[051] ELISAs are performed using a polyclonal rabbit anti-human FIX (Accurate Chemical, Westbury, NY) in a 1:40000 dilution as primary antibody, and a polyclonal goat anti-human FIX horseradish-peroxidase conjugate as detection antibody. As a standard, a human plasma-derived FIX (Enzyme Research Laboratories, S. Lafayette, IN) is used. APTT is determined using a STA Compact automated coagulometer (Diagnostica Stago, Asnieres, France) by diluting FIX-samples into FIX deficient plasma. All reagents for clotting are purchased from Baxter, Vienna, Austria.

Results

[052] Two stable rFIX-producing cell lines, one CHO- and one HEK293-derived, are subjected to transient transfections with the expression vector pCMV-VKORC1-EDHpro carrying a cDNA encoding human VKORC1. As controls, the empty vector pCMV-EDHpro and the stable rFIX-expressing cell line are used. After transient transfections, the cells are left overnight in serum-containing medium. The cells are washed with PBS and cultivated for 24 hours in serum-free medium, then the supernatants are harvested. rFIX expression and secretion into the medium is monitored by immunochemical and coagulation diagnosis methods measuring antigen level or clotting activity. To estimate effects on cellular productivity, the secretion rates are calculated on the basis of product concentration per cell number and 24 hours (Fig. 1 to Fig. 4).

[053] HEK293 cells expressing rFIX shows a 2.7-fold mean increase of specific secretion rates and a 2.9-fold increase of rFIX-concentrations after rVKORC1 transfection in comparison to the empty vector control. These values are based on APTT measurements. ELISA values shows a 2.0-fold increase of concentrations, and a 1.8-fold increase of specific productivities.

[054] For the CHO-derived rFIX-producer cell line, a 1.5-fold increase of ELISA-titers, and a 1.2-fold increase of ELISA-based specific secretion rates are observed. APTT-calculated secretion rates are 1.4-fold higher, and APTT-measured FIX concentrations 1.7-fold.

[055] From these values it can be concluded that for both different cell types higher rFIX product concentrations in presence of rVKORC1 can be achieved, mainly because of a higher cell specific rFIX secretion rate. A reason for a higher secretion rate of rFIX molecules with complete γ -carboxylation could be a cellular quality control mechanism for this post-translational modification (Lin, P.J., Straight, D.L., & Stafford, D.W. (2004) Binding of the factor IX gamma-carboxyglutamic acid domain to the vitamin K-dependent gamma-glutamyl carboxylase active site induces an allosteric effect that may ensure processive carboxylation and regulate the release of carboxylated product. *J.Biol.Chem.*, 279, 6560-6566). Higher increases of APTT values than ELISA values in case of both cell lines indicate also a better FIX-clotting activity.

[056] Stronger effects of rVKORC1 on rFIX co-expression in HEK293-derived cells than in CHO cells can be explained by a higher cellular rFIX-productivity. Before transient VKORC1 transfections, the 293-derived clone has a 3.5-fold higher productivity than the CHO-clone in respect of APTT values, but a 5-fold higher productivity regarding ELISA values. This indicates a lower post-translational processing degree in the 293-derived cells because of a higher productivity. Therefore, a higher yield of active rFIX isoform when restoring γ -carboxylation capacity by rVKORC1 co-expression is found in this cell line.

Example 2: Transient co-expression of recombinant human VKORC1 in CHO- and HEK293-derived mammalian cell lines stably producing recombinant human coagulation factor VII (rFVII)

[057]Any influence of rVKORC1 on the activity and/or secretion rate of rFVII can be studied by transient co-expression in human recombinant coagulation factor VII (rFVII) producing cells. Thus, a major part of the rFVII producing cell population also co-expresses VKORC1 for a short period of time. During this period, the secreted rFVII can be sampled, characterized and compared to the rFVII secreted by the same cell lines transfected in parallel with an empty vector control.

[058]The stable expression of rFVII in mammalian cells can be achieved by transfecting plasmid vectors containing the human rFVII cDNA and selection resistance genes and subsequent producer clone selection. The same host cell lines as listed in Example 1 can be used for stable expression of rFVII. Genetic selection and gene amplification procedures, and the screening for producer clones have to be performed analogically.

[059]After that, an expression vector carrying the human VKORC1 cDNA can be transfected transiently to achieve co-expression of recombinant VKORC1 (rVKORC1) in the same way as described in Example 1.

Materials and methods

Expression vectors

[060]An expression vector comprising human rFVII genetic information can be constructed by isolating human FVII cDNA by PCR from an appropriate source like the vaccinia expression vector pselp/huFVII (Himly et al., 1998) as template. The PCR-product can be inserted via restriction sites into a mammalian expression vector offering a strong viral promoter as from cytomegalovirus (CMV) and an additional

antibiotic selection marker like the neomycin or hygromycin resistance gene, for Example pcDNA3.1/hyg+ or pcDNA3.1/neo+ (Invitrogen, Carlsbad, CA).

[061]For stable gene expression in the CHO-DHFR⁻ expression system an additional plasmid like pSV-DHFR as described in Example 1 can be used to enable selection of DHFR-containing cell clones and MTX-gene amplification.

[062]The vector pCMV-VKORC1-EDHpro as described in Example 1 can be used for transient expression of rVKORC1.

Cell culture and transfections

[063]The same cell lines and cultivation protocols can be used as described in Example 1. To generate stable transfectants, a calcium-phosphate co-precipitation method can be used. Plasmids have to be linearized by restriction enzyme digestion before transfections. A mammalian expression vector containing FVII cDNA can be used for stable transfection of CHO or HEK293 host cell lines. CHO DUKX DXB11 cells must be co-transfected with pSV-DHFR. If hygromycin B is used as selecting agent, its concentration should be 100 µg/mL in the medium to select HEK293-derived transfectants, and 250 µg/mL in case of CHO-transfectants. If neomycin resistance is used as selection marker, the concentrations of G418 should be adjusted as described in Example 1 for each cell type.

[064]Transient transfection protocols include the use of Lipofectamine™ 2000 reagent as described in Example 1. To enable comparison of cells expressing rVKORC1 transiently with an adequate negative control, the vector pCMV-VKORC1-EDHpro and the same vector without the VKORC1 cDNA sequence should be transfected in parallel in several replications, preferably in 6-well plates. Cells derived from the same population are distributed at equal cell densities per well. At confluency, all transfections are performed simultaneously.

[065]rFVII secretion into cell culture supernatants can be detected by exchanging the growth medium for serum-free medium supplemented with varying vitamin K1

concentrations ranging from 0.1 to 10 µg/mL. Supernatants can be collected after 24 hours and rFVII concentrations can be determined by appropriate methods as described below. For the calculation of specific rFVII secretion rates, cells should be counted for example by using a CASY cell counter (Schärfe Systems, Reutlingen, Germany), or the trypan-blue exclusion method.

Analytical assays

[066] To screen for rFVII producer clones, and to relate FVII-activities with antigen levels, the following assays are appropriate:

[067] FVII activity can be measured in a clotting assay as prothrombin clotting time (PT) or in a chromogenic assay according to European Pharmacopeia (European Pharmacopeia 5, 2005) as amount of clotting factor Xa (FXa) generation quantified by conversion of a chromogenic FXa substrate. FVII antigen levels can be determined by ELISA using appropriate antibody pairs, for example an affinity purified polyclonal sheep anti-human FVII antiserum (Affinity Biologicals, Ancaster, Canada) diluted 1:3000 for capture, and a polyclonal sheep anti-human FVII horseradish peroxidase conjugate (Cedarlane, Ontario, Canada; 1:2000 diluted) for detection, followed by addition of an appropriate chromogenic reagent for photometric detection.

[068] For all assays, plasma-derived FVII preparations should be used as standard material, which are assayed against the international FVII standard 97/592. Relative specific clotting activities can be estimated by calculating ratios of measured antigen to activity values and comparing these internally or with values of plasma-derived or FVII preparations.

[069] To estimate FVIIa levels as part of total secreted rFVII, the following assays can be used: The Staclot® assay (Diagnostica Stago, Asnieres, France) is adequate to measure a FVIIa prothrombin clotting time selectively (Morrissey et al., 1993). FVIIa levels should be assayed against international FVIIa standard 89/688.

Results

[070] A stable rFVII-producing CHO-derived cell line is subjected to transient transfections with a VKORC1 encoding expression vector pCMV-VKORC1-EDHpro. As a control, the empty vector pCMV-EDHpro without the VKORC1-encoding cDNA can be used. Cells are seeded into 6-well plates at cell concentrations of 1×10^6 cells per well. When confluency is reached, the transient transfection procedure is performed in duplicates. After overnight incubation, the cells are incubated in serum-free medium without any vitamin K1 to deplete the cells' internal vitamin K1 reservoirs from FBS-supplies. After 24 hours, the medium is exchanged for serum-free medium containing vitamin K1 at various concentrations ranging from 0 to 5 $\mu\text{g/mL}$. The supernatants are collected for further analysis. Productivities per 24 hours are determined from rFVII-antigen and activity concentration values as measured by ELISA and one-stage clotting assays. Specific FVII clotting activity is calculated as FVII-clotting-units per μg antigen. To estimate the degree of auto-activation of rFVIIa to rFVIIa, the Staclot® assay can be used. In Figs. 6A, 6B and 6C, the results of these experiments are shown.

[071] After transient transfection with both vector constructs, rFVII- expression levels are determined by ELISA (Fig. 6A) and FVII-clotting (Fig. 6B). There are no significant amounts of rFVIIa produced by the cell line, therefore rFVII-activity can be correlated to rFVII-productivity.

[072] Without vitamin K1 in the medium, the cellular productivity and specific activity of the produced rFVII are significantly lower with and without rVKORC1 co-expression. In case of rVKORC1-co-expression, rFVII productivity recovers at 0.1 $\mu\text{g/mL}$ to a 4-fold higher value as the control transfection with empty vector, as measured by both clotting and ELISA. rVKORC1-co-expression improves usage of vitamin K1 added to the cell culture medium regardless of the vitamin K1-concentration. In general, rFVII-productivity, determined by two different methods, is up to four times higher than the control at all vitamin K1 concentrations with rVKORC1 co-expression. Specific activity as expressed in clotting units per μg rFVII

produced shows significant lower values only at 0 µg/mL vitamin K1, and does not show significant differences with and without rVKORC1.

[073]When comparing CHO-derived with HEK293-derived cell lines stably expressing rFVII after transient rVKORC1-co-expression in a similar experiment, significant higher productivities can be found as the control transfection in both cases (Fig. 7). In this experiment, 0.5 µg/mL vitamin K1 are used. For CHO-rFVII cells, a 2.5-fold higher rFVII expression level with rVKORC1 co-expression than the control can be found as determined by clotting and ELISA.

[074]It can be concluded that γ -carboxylation is a rate limiting step for productivity of rFVII, when reduced vitamin K form required for this reaction is not available in sufficient amounts. A putative cellular control mechanism retains rFVII-molecules with incomplete γ -carboxylation inside the cell (Lin et al., 2004). Transient rVKORC1 co-expression improves rFVII productivity at a broad range of vitamin K1 concentrations by providing better supply of reduced vitamin K form ensuring complete γ -carboxylation.

[075]These findings are again in accordance with previous works, where co-expression of γ -carboxylase led to a decrease of recombinant human factor IX productivity in mammalian cells (Hallgren et al., 2002). The only known function of VKORC1 within cellular metabolism to-date is the reduction of Vitamin K-2,3 epoxide to the hydroquinone form necessary for the γ -carboxylation reaction. Even if mammalian cell lines possess a well-functioning γ -carboxylation machinery *per se*, it can be concluded that rVKORC1 co-expression guarantees the desired rFVII protein quality of complete γ -carboxylation.

Example 3: Stable bicistronic co-expression of rVKORC1 and rFVII in CHO-derived cell lines after non-viral gene transfection

[076]To make use of any effect of rVKORC1 co-expression on γ -carboxylation within the scope of generating stable mammalian cell lines for rFVII production, a bicistronic

expression system can be used. With such a system, the simultaneous expression of two proteins in eukaryotic cells after delivery of a single expression vector can be achieved. Moreover, the two proteins are translated from the same mRNA molecule simultaneously. This is enabled by introduction of a viral genetic element termed internal ribosome entry sequence (IRES) between the cDNAs encoding the two transgenes into the expression vector construct (Mountford and Smith, 1995). After transcription of the mRNA from the DNA vector construct, which has been integrated stably into the host cell chromosome, two ribosomes can bind to the processed mRNA leading to simultaneous elongation of both polypeptide chains.

[077]A vector has to be constructed providing elements for mammalian expression, for example strong viral promoters, polyadenylation signals and resistance genes enabling clone selection. Both cDNAs encoding the desired proteins are cloned into the vector with an IRES sequence in-between.

[078]To compare rFVII expression with bicistronic rFVII and rVKORC1 co-expression, a control expression vector derived from exactly the same host vector carrying rFVII cDNA only can be constructed. These two vectors can be transfected in parallel into the same host cell line, for example the CHO-DHFR⁻ cell line CHO DUXK DXB11. This cell line offers the opportunity to enhance protein expression levels by gene amplification. This can be achieved by co-transfection of a plasmid carrying the DHFR gene and by increasing levels of the drug MTX during sub-cultivation as described in Example 1. By comparing the co-expression vector with the monocistronic rFVII vector in this expression and co-amplification system, the effects of gene-amplification on rFVII expression levels and activities in presence or absence of rVKORC1 as a helper protein can be observed. The selection of rFVII producer clones and characterization of produced rFVII can be achieved as explained in Example 2. To avoid clone-specific bias when comparing the two expression systems, a large number of clones, which have been screened by the same methodology, should be characterized.

Materials and methods

Expression vectors

[079] Plasmid vector constructs, which are derived from the same host vector as explained in Example 2, can be constructed by standard cloning techniques. The construction of the vector pCMV-rFVII can be accomplished as described in Example 2, the analogue vector pCMV-rFVII-IRES-VKORC1 can be constructed as follows: the human FVII cDNA can be amplified via PCR from the same source as used in Example 2. The IRES element can be isolated from the source vector pIRES2-EGFP (Clontech, Palo Alto, CA), and the VKORC1 cDNA can be cloned from the same source vector as described in Example 1 (pCEP4-VKORC1). All three elements can be cloned into the same host vector as used for construction of pCMV-rFVII (see Example 2). In detail, the FVII cDNA PCR product with an added Kozak's sequence and EcoRI restriction sites can be cloned into an intermediate vector (e.g. pBluescript; Stratagene, LaJolla, CA) to enable cleavage via appropriate restriction sites. A HindIII/BamHI fragment of this intermediate vector containing FVII cDNA can be cloned into pcDNA3.1/Hyg+ (Invitrogen). This intermediate construct can be digested with BamHI and XhoI to enable insertion of a BamHI/BstXI fragment from pIRES2-EGFP (containing IRES) together with a PCR product with VKORC1 cDNA (obtained from template pCEP4-VKORC1) and BstXI and XhoI sites at 5' and 3' ends simultaneously in one ligation reaction to obtain pCMV-rFVII-IRES-VKORC1.

[080] To enable gene expression and amplification in the CHO-DHFR⁻ expression system, a second selection plasmid pSV-DHFR as described in Example 1 can be used.

Cell culture and transfections

[081] The CHO-DHFR⁻ host cell line and the same materials and transfection and cultivation protocols as described in Example 1 can be used for the generation and selection of desired rFVII producer clones. Gene amplification with MTX can be accomplished analogically.

Analytical assays

[082] To characterize clones and supernatants for rFVII or activity and concentration, and to determine cell-specific productivity, the same assays as described in Example 2 can be used. FVIIa activity has to be monitored analogically.

Northern blots

[083] This technique can be used to detect transcription of the introduced genes specifically at mRNA level, and to check for correct mRNA sizes. Total cellular RNA isolated and prepared from a cell population can be separated on an agarose gel and blotted onto a nylon membrane. The specific RNA sequences can be detected via hybridization of a DIG-labeled Probe and developed with an alkaline-phosphatase-labeled anti DIG antibody (Roche, Basel, Switzerland) after binding to the hybridized probe by chemoluminescence on x-ray film. The target mRNA-levels (rVKORC1 and rFVII) should be compared against a house-keeping gene (e.g. hamster glyceraldehyde-phosphate-dehydrogenase (GAPDH)).

Results

[084] Stable cell clones derived from the CHO-DHFR⁻ expression systems can be generated and assayed for rFVII productivity by ELISA and prothrombin-time (PT) clotting techniques. The expression plasmids pCMV-rFVII-IRES-VKORC1 or pCMV-rFVII can be co-transfected with the selection plasmid pSV-DHFR by calcium-phosphate co-precipitation technique, and clones can be obtained by exposition to selection medium lacking hypoxanthine, glycine and thymidine and to antibiotic selection. Single-cell derived clones are screened after limited dilution cloning and are subcultivated several times with increasing MTX concentrations to achieve gene-amplification. Clones are exposed to MTX concentrations of up to 320 nM with every subcloning step. From all subcloning rounds, a total of 133 clones derived from pCMV-rFVII transfections and 83 clones derived from transfections with the rVKORC1 co-expression construct are expanded and characterized in detail. For cell culture supernatants, rFVII concentrations can be determined by ELISA, rFVII and rFVIIa activities are measured by PT clotting assays in parallel. Only clones with less than 10 % of rFVII activated to FVIIa are considered for characterization to avoid artificially high specific FVII-clotting values (data not shown). The expression levels

are calculated from ELISA concentration values as ng per 10^6 cells per 24 hours. Specific FVII-clotting activity is calculated as clotting units per μg .

[085] In Fig. 8, specific productivity values on ELISA basis are plotted against MTX concentrations for rFVII only expressing clones (Fig. 8A), and rFVII-rVKORC1 co-expressing clones (Fig. 8B) respectively. In both lines a relationship between MTX levels and expression levels is visible. Initial clones at no MTX start at comparable, or even higher levels for the rFVII-only clones. Especially, when MTX is increased to low starting levels of 20 to 40 nM, a pattern of steeper concomitant increase of expression levels for rFVII-rVKORC1 co-expressing clones is clearly visible in Fig. 8A versus Fig. 8B. At 80 nM MTX, all rFVII-rVKORC1 co-expressing clones express 2 to 80 times more rFVII than initial clones, whereas for the rFVII-only clones, still some clones are found with expression levels similar to initial clones. From 20 nM upwards, better producer clones are found within rFVII-rVKORC1 than rFVII-only clones at all MTX levels. It can be seen, that the expression level of better rFVII-producer clones after gene amplification is two times higher with rVKORC1-co-expression especially at initial rounds of MTX increase.

[086] Regarding specific FVII-clotting activity, the values calculated for all of these clones can be plotted against productivity to compare protein functionality. In Fig. 9, both lines are compared showing about equal activity values at similar productivity ranges with an overall decline at higher productivity for both. As rFVII-rVKORC1 co-producers with more than twofold higher productivity are found, the activity values at a range higher $4 \mu\text{g}$ per 10^6 cells per day cannot be compared. Above this expression level in rFVII-rVKORC1 clones, a constant activity value of 2 U per μg similar to plasma-derived FVII (Moor et al., 1995) can be maintained.

[087] The functionality and functional genomic integration of the vector construct including the IRES element leading to transcription of a single bicistronic mRNA containing rFVII and rVKORC1 encoding sequences can be demonstrated by northern blotting technique, especially if there is no VKORC1-specific assay available.

[088]Fig. 10 shows an example of a northern blot, where total mRNA of CHO-derived transfectant or control cells has been isolated after cell lysis, and has been blotted on a nylon membrane after electrophoretic separation. The membrane has been hybridized three times subsequently with DIG-labeled DNA probes specific for human VKORC1, for human FVII, and for a reference gene, hamster GAPDH. Probes are detected with DIG-specific labeled antibodies. The samples are: non-transfected CHO-DHFR⁻ cells, one CHO-derived clone expressing rFVII only, two clones, which have been transfected with rFVII- and rVKORC1-encoding vectors subsequently as described in Example 3, and three clones with bicistronic rFVII and rVKORC1 co-expression. mRNA transcripts with sizes of approximately 2.4 kb for the rFVII-IRES-rVKORC1 construct, of 1.4 kb for the rFVII construct, 0.5 kb for the rVKORC1 mRNA, and 1.0 kb for the GAPDH control mRNA, can be detected with all three probes. GAPDH can be found in all clones, whereas rVKORC1 and rFVII are present according to transfected plasmid vectors in the respective cell lines.

[089]In summary, the stable bicistronic co-expression of rVKORC1 has an enhancing effect on productivity of rFVII in mammalian cells, especially when gene amplification is applied. The yield of rFVII-high-producer clones after gene transfer is higher with rVKORC1-co-expression. With half the number of clones screened, two-fold higher expression levels can be achieved at same MTX concentration levels. Protein activity can be maintained at high cellular protein secretion levels. Both effects can be explained by sufficient supply of reduced vitamin K form required for the γ -carboxylation reaction, which has to take place at a high turnover rate at high protein secretion levels to ensure timely release of the completely carboxylated protein.

Example 4: Stable co-expression of rFVII and rVKORC1 after two subsequent non-viral transfections in CHO or HEK293 mammalian cells

[090]To verify rVKORC1 effects as helper protein on rFVII recombinant expression in mammalian cell culture, another approach can be used to achieve co-expression of

rVKORC1 together with rFVII. A strategy to select for clones showing stable rFVII and rVKORC1 co-expression after a second transfection can be employed. A clone, which has been selected for rFVII expression after stable transfection, can be transfected a 2nd time with another plasmid vector encoding human VKORC1. A second resistance marker can be introduced to ensure a selection step by resistance to another antibiotic. As an appropriate control, the same vector without VKORC1 cDNA can be transfected in parallel into the same cell population. From these transfections, stable clones can be isolated after simultaneous selection with two antibiotics within a cloning step and characterized as described in Examples 2 and 3. A comparison of these newly isolated clones should enable conclusions of rVKORC1 co-expression effects on rFVII productivity and activity.

Materials and Methods

Expression vectors

[091] To generate clones producing rFVII, the same expression vectors and source of rFVII cDNA as listed in Example 2 can be used. For the CHO-DHFR⁻ system, an additional selection plasmid pSV-DHFR can be used.

[092] To achieve rVKORC1 co-expression after a second transfection, a vector encoding human VKORC1 and a different antibiotic selection marker as used for the first transfection can be taken. This vector can be constructed by insertion of a PCR product generated from the same template as described in Example 1 into a pcDNA3.1 based vector (Invitrogen). In that case, the same pcDNA3.1 vector without insert should be taken for the 2nd control transfection. Alternatively, the vector pCMV-VKORC1-EDHpro as described in Example 1 can be taken as expression vector for the same transfection. As control plasmid, the empty vector pCMV-EDHpro (reference see Example 1) can be used.

Cell culture and transfections

[093] The same cell lines as used in Example 1, CHO and HEK293, can be used to generate stable cell lines producing rFVII. All cell culture media, transfection and cultivation protocols can be used accordingly. To achieve stable co-expression of

rVKORC1 in these cell lines, a second transfection using calcium-phosphate co-precipitation can be used. Another cloning step using an additional antibiotic selection drug is necessary to obtain clones with rFVII and rVKORC1 co-expression.

Analytical assays

[094] The same assays for concentration and activity measurements as described in Examples 2 and 3 can be used to verify rFVII expression. rVKORC1 transcription at mRNA level can be shown by northern blot technique as described in Example 3.

Results

[095] To demonstrate an effect of the rVKORC1 helper protein on the expression of rFVII, an approach of two subsequent transfections and cloning rounds can be employed. In the first round, cell clones expressing rFVII can be isolated by appropriate screening techniques after stable transfection and antibiotic selection. One of these clones can be expanded and used for a second transfection with a human VKORC1-encoding plasmid or an empty control plasmid. Another selection marker can be introduced. Again, clones can be screened for rFVII expression by appropriate techniques, after addition of the second antibiotic selection drug to the medium, thus ensuring depletion of non-transfected cells. Clones originating from rVKORC1- or control transfections can be compared in terms of rFVII productivity or activity. The empty control vector ensures comparison of clones being exposed to the same cultivation conditions with influence on rFVII expression, especially double-antibiotic selection.

[096] Typically, from all clones derived from successfully transfected cells, a small number of clones is selected according to their rFVII productivity and expanded for further characterization. This characterization includes determination of secreted rFVII concentrations by antigen ELISA technique and by measurement of rFVII and rFVIIa clotting activities. The co-expression of rVKORC1 and rFVII can be verified at mRNA level by northern blot technique as shown for two CHO-derived clones in Fig. 10, lanes 3 and 4.

[097] In Fig. 11, specific productivity values based on ELISA titers in culture supernatants are shown for a range of selected clones originating from rVKORC1 2nd transfections or control transfections of a CHO-derived (Fig. 11A) and a HEK293-derived (Fig. 11B) rFVII-producing cell line. It can be seen for both cell types, that clones derived from the rVKORC1 transfection produce more rFVII than those originating from the control transfection. The median value of all productivities is approximately two times higher for rVKORC1 clones in both cases.

[098] In Figs. 12A and 12B, the specific rFVII clotting activities given as FVII clotting units per microgram ELISA are shown for clones derived from both cell types after 2nd transfections. For specific activity calculations, clones with a high amount of rFVII activation to rFVIIa, which can be measured by FVIIa-specific clotting assay, should not be considered. A value of 10 % FVIIa clotting units per FVII clotting units can be chosen to exclude clones producing a significant amount of rFVII activated to rFVIIa. Therefore less clones are shown in Fig. 12 than in Fig. 11.

[099] Differences in specific FVII-clotting activity can be correlated rather with expression level than with rVKORC1 co-expression. However, in case of CHO-derived clones, clones with similar expression levels show higher activity in presence of rVKORC1 co-expression. Concerning productivity for both CHO- and HEK293-derived cell clones, it can be concluded that rVKORC1 co-expression leads to a two-fold mean improvement in comparison to a control. Moreover, it can be concluded, that rFVII activity is also affected by other factors influenced by the cell's metabolic protein secretion and modification capacity in addition to γ -carboxylation. Productivity and activity values are in agreement with results of rFVII/rVKORC1 co-expression experiments as described in Examples 2 and 3.

List of references

European Pharmacopeia 5. Assay of Human Coagulation Factor VII. 5th Edition
2.7.10, 203. 2005.

Ref Type: Generic

Hallgren, K.W., Hommema, E.L., McNally, B.A., and Berkner, K.L., 2002.
Carboxylase overexpression effects full carboxylation but poor release and secretion
of factor IX: implications for the release of vitamin K-dependent proteins.
Biochemistry 41, 15045-15055.

Himly, M., Pflleiderer, M., Holzer, G., Fischer, U., Hannak, E., Falkner, F.G., and
Dorner, F., 1998. Defective vaccinia virus as a biologically safe tool for the
overproduction of recombinant human secretory proteins. Protein Expr.Purif. 14,
317-326.

Lin, P.J., Straight, D.L., and Stafford, D.W., 2004. Binding of the factor IX gamma-
carboxyglutamic acid domain to the vitamin K-dependent gamma-glutamyl
carboxylase active site induces an allosteric effect that may ensure processive
carboxylation and regulate the release of carboxylated product. J.Biol.Chem. 279,
6560-6566.

Moor, E., Silveira, A., van't Hooft, F., Suontaka, A.M., Eriksson, P., Blomback, M.,
and Hamsten, A., 1995. Coagulation factor VII mass and activity in young men with
myocardial infarction at a young age. Role of plasma lipoproteins and factor VII
genotype. Arterioscler.Thromb.Vasc.Biol. 15, 655-664.

Morrissey, J.H., Macik, B.G., Neuenschwander, P.F., and Comp, P.C., 1993.
Quantitation of activated factor VII levels in plasma using a tissue factor mutant
selectively deficient in promoting factor VII activation. Blood 81, 734-744.

Mountford, P.S. and Smith, A.G., 1995. Internal ribosome entry sites and dicistronic
RNAs in mammalian transgenesis. Trends Genet. 11, 179-184.



CLAIMS



1. A host organism containing a recombinant nucleic acid coding for a vitamin K reductase complex subunit 1 (VKORC1) or a functionally active derivative thereof, and a recombinant nucleic acid coding for a vitamin K dependent (VKD) protein or a functionally active derivative thereof, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said host organism.
2. The host organism of claim 1, wherein either the nucleic acid coding for recombinant VKORC1 or the nucleic acid coding for the recombinant VKD protein or both are expressed via an expression mode selected from the group consisting of induced, transient, and permanent expression.
3. The host organism of claim 1 or 2, wherein the host organism is a mammalian cell.
4. The host organism of claim 3, wherein the mammalian cell is a cell derived from a mammalian cell line selected from the group consisting of CHO cells and HEK293 cells.
5. The host organism of anyone of claims 1 to 4, wherein the recombinant VKD protein is a procoagulant blood factor or a functionally active derivative thereof.
6. The host organism of claim 5, wherein the procoagulant blood factor is selected from the group consisting of factor II, factor VII, factor IX and factor X.
7. The host organism of claim 6, wherein the procoagulant blood factor is human factor IX.



8. A cell culture system comprising cells which contain a recombinant nucleic acid coding for a vitamin K reductase complex subunit 1 (VKORC1) or a functionally active derivative thereof and a recombinant nucleic acid coding for a vitamin K dependent (VKD) protein or a functionally active derivative thereof, wherein both the recombinant VKORC1 and the VKD protein are expressed in said cells.
9. The cell culture system of claim 8, wherein the cultured cells are mammalian cells.
10. The cell culture system of claim 9, wherein the mammalian cells are selected from the group consisting of CHO cells and HEK293 cells.
11. The cell culture system of claim 8 to 10, wherein the recombinant VKD protein is a procoagulant blood factor or a functionally active derivative thereof.
12. The cell culture system of claim 11, wherein the procoagulant blood factor is selected from the group consisting of factor II, factor VII, factor IX and factor X.
13. The cell culture system of claim 12, wherein the procoagulant blood factor is human factor IX.
14. A method for improving the productivity of recombinant vitamin K dependent (VKD) protein expression or of a functionally active derivative thereof in a host organism comprising the steps of:
 - (a) providing a host organism;
 - (b) inserting a recombinant nucleic acid coding for a VKD protein or a functionally active derivative thereof into the host organism of step (a);



- (c) inserting a recombinant nucleic acid coding for a vitamin K reductase complex subunit 1 (VKORC1) or a functionally active derivative thereof into the host organism of step (a); and
 - (d) expressing the recombinant nucleic acids of steps (b) and (c).
15. A method for improving the productivity of recombinant vitamin K dependent (VKD) protein expression or of a functionally active derivative thereof in a host organism comprising the steps of:
- (a) providing a host organism having a recombinant nucleic acid coding for a VKD protein or a functionally active derivative thereof integrated into its genome;
 - (b) inserting a recombinant nucleic acid coding for a vitamin K reductase complex subunit 1 (VKORC1) or a functionally active derivative thereof into the host organism of step (a); and
 - (c) expressing the nucleic acids of steps (a) and (b).
16. The method of claim 15, wherein the recombinant nucleic acid coding for a VKD protein or a functionally active derivative thereof is stably expressed.
17. A method for improving the productivity of recombinant vitamin K dependent (VKD) protein expression or of a functionally active derivative thereof in a host organism comprising the steps of:
- (a) providing a host organism having a recombinant nucleic acid coding for a vitamin K reductase complex subunit 1 (VKORC1) or a functionally active derivative thereof integrated into its genome;



- (b) inserting a recombinant nucleic acid coding for a VKD protein or a functionally active derivative thereof into the host organism of step (a);
and
 - (c) expressing the nucleic acids of steps (a) and (b).
18. The method of claim 17, wherein the recombinant nucleic acid coding for VKORC1 or a functionally active derivative thereof is stably expressed.
19. A recombinant vitamin K dependent (VKD) protein obtainable by inserting a recombinant nucleic acid coding for a vitamin K reductase complex subunit 1 (VKORC1) or a functionally active derivative thereof and a recombinant nucleic acid coding for said recombinant VKD protein or a functionally active derivative thereof into a host organism, expressing said nucleic acids, and recovering said recombinant VKD protein.

A**B****Figure 1**

A**B****Figure 2**

A**B****Figure 3**

A**B****Figure 4**

A**B****Figure 5**




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2006/000734

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12N9/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WAJIH NADEEM ET AL: "Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity - Evidence for a functional CXXC redox center in the system" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 11, March 2005 (2005-03), pages 10540-10547, XP002377554 ISSN: 0021-9258 published online on 7 January 2005 abstract page 10544; figure 3 page 10545, right-hand column, line 6 - page 10546, left-hand column, line 8; figure 4 ----- -/--	1-19

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

20 April 2006

Date of mailing of the international search report

11/05/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Grötzing, T

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2006/000734

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>WAJIH NADEEM ET AL: "Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 36, September 2005 (2005-09), pages 31603-31607, XP002377555</p> <p>ISSN: 0021-9258</p> <p>abstract</p> <p>page 31606; table 1</p>	1-19
P,X	<p>SUN YAN-MEI ET AL: "Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X"</p> <p>BLOOD, vol. 106, no. 12, December 2005 (2005-12), pages 3811-3815, XP002377556</p> <p>ISSN: 0006-4971</p> <p>abstract</p> <p>page 3812, left-hand column, paragraphs 3,5</p> <p>page 3813; figure 2</p>	1-19
P,X	<p>WO 2005/040367 A (BAXTER INTERNATIONAL INC; BAXTER HEALTHCARE S.A; OLDENBURG, JOHANNES;) 6 May 2005 (2005-05-06)</p> <p>abstract</p> <p>page 48, paragraph 127</p>	1-19
Y	<p>ROST S ET AL: "Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2"</p> <p>NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 427, no. 6974, 5 February 2004 (2004-02-05), pages 537-541, XP002318816</p> <p>ISSN: 0028-0836</p> <p>abstract</p>	1-19
Y	<p>LI TAO ET AL: "Identification of the gene for vitamin K epoxide reductase"</p> <p>NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 427, no. 6974, 5 February 2004 (2004-02-05), pages 541-544, XP002318817</p> <p>ISSN: 0028-0836</p> <p>abstract</p>	1-19

-/--

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2006/000734

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WALLIN REIDAR ET AL: "Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system." THROMBOSIS RESEARCH, vol. 108, no. 4, 2002, pages 221-226, XP002377557 ISSN: 0049-3848 abstract</p> <p>-----</p>	1-19

Form PCT/ISA/210 (continuation of second sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2006/000734

Patent document
cited in search report

Publication
date

Patent family
member(s)

Publication
date

WO 2005040367

A

06-05-2005

NONE